Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD

International Journal of Clinical Practice

Volumn 53, Issue 3, 1999, Pages 185-188

  Sichletidis, Lazaros ^a   Kottakis, J ^a   Marcou, S ^a   Constantinidis, T C ^a   Antoniades, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SPIROMETRY;

ADULT; AGED; AREA UNDER CURVE; BRONCHI; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; SINGLE-BLIND METHOD;

EID: 0032904316     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Rennard SI. Combination bronchodilator therapy in COPD. Chest 1998; 107(suppl 5): 1715-1755.
2. Combivent Inhalational Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994; 105: 1411-1419.
3. Lightbody IM, Ingram CG, Legge JS et al. Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis. Br J Dis Chest 1978; 72(3): 181-186.
4. Casali L, Grassi C, Rampulla C, Rossi A. Clinical pharmacology of a combination of bronchodilators. Int J Clin Pharmacol Biopharm 1979; 7: 277-280.
5. Crassi V, Brunni B, Peccini F et al. Acute and chronic comparative effects of a combination of fenoterol-ipratropium bromide and terbutaline in patients with chronic obstructive lung disease. Respiration 1986; 50(supp] 2): 226-231.
6. Lees AW, Allan GW, Smith J. Nebulised ipratropium bromide and salbutamol in chronic bronchitis. Br J Clin Pract 1980; 34: 340-347.
7. Wesseling G, Moster R, Wouters EFM. A comparison of the effects of anticholinergic and beta-2 agonist and combination therapy in respiratory impedance in COPD. Chest 1992; 101: 166-173.
8. Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995; 107(2): 401-405.
9. Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide) given by aerosol alone or in sequence. N Engl J Med 1985; 315: 735-739.
10. Lloberes P, Ramis L, Montserrat JM et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J 1988; 1: 536-539.
11. Le Doux EJ, Morris JF, Temple WP et al. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Chest 1989; 95: 1013-1016.
12. Siafakas NM, Vermeire NB, Pride NB et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.
13. Matera MG, Cazzola M, Vinciguerra A et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995; 8: 267-271.
14. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996; 90: 497-499.
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1995; 152(5): s77-s120.
16. Karpel JP, Pesin J, Greenberg D et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990; 98: 835-839.
17. Shiveram U, Cash ME, Mateo F, Shim C Effects of high-dose ipratropium bromide and oral aminophylline on spirometry and exercise tolerance in COPD. Respir Med 1997; 91(6): 327-334.
18. Dor A, Krasnowska M, Malolepszy J. Effect of vaporizing high doses of ipratropium bromide in patients with chronic obstructive pulmonary disease and bronchial asthma. Pneumonol Alergol Pol 1994; 62(1-2): 75-79.